共查询到20条相似文献,搜索用时 171 毫秒
1.
《实用医药杂志(山东)》2014,(11)
<正>超重和肥胖症是心血管病、糖尿病、某些癌症和其他一些慢性疾病的重要危险因素。肥胖症的传统治疗方法包括改变生活方式和药物治疗等,但极少能达到长期而显著减肥的目的。置入胃内水球(bioenterics intragastric balloon,BIB)是种行为治疗,目的为帮助患者纠正不正常的饮食习惯。西方已证实它对诱导早期出现饱腹感从而减轻体重非常有效[1]。现将笔者所在医院运用胃内水球的101位超重或肥胖症患 相似文献
2.
胃内水球术减肥治疗一例 总被引:2,自引:0,他引:2
目前肥胖症已成为全球流行病,肥胖会引发许多疾病,导致不良后果。如何控制肥胖及其相关并发症已引起广泛重视。胃内水球(BioEnterics Intragastric Balloon,BIB)是一种非手术非药物的减肥方法。目前。该方法在国外许多国家已被广泛应用.其有效性和安全性得到充分的认可。我院于2005年9月30日成功地为一位肥胖患者行胃内水球治疗,现报告如下。 相似文献
3.
4.
目的对胃大部切除术后胃瘫的诊断及治疗方法进行探讨。方法14例胃大部切除术后胃瘫患者均给予非手术治疗。回顾性分析术后胃瘫的临床表现、诊断方法及治疗效果。结果根据病史、症状、体征以及胃镜、X线胃钡餐造影检查结果,可明确胃瘫的诊断。经过非手术治疗,14患者例均于术后10~42d恢复胃排空功能,其中6例患者在2—3周内恢复,4~6周内恢复者8例,无再次手术者。随访半年无复发。结论术前行胃肠减压和洗胃、解除患者焦虑紧张心理,术中规范操作,术后循序渐进进食等,是预防术后胃瘫的重要措施,早期明确诊断、规范进行非手术治疗,可获满意效果。 相似文献
5.
王华云 《中国现代药物应用》2013,7(1):78-79
目的探讨应用护理方法对胃癌术后胃瘫的康复效果的影响。方法回顾性分析2005年1月至2011年1月我院22例胃癌手术后胃瘫患者的临床资料及护理经验。结果经过保守治疗,本组22例胃瘫患者中,术后三周内胃动力恢复12例,术后三.四周胃动力恢复6例,术后四周-三月胃动力恢复4例,22例患者均痊愈出院,收到了良好的护理效果。结论采用完善的综合治疗及护理方法,可以协助胃癌术后胃瘫患者康复出院。 相似文献
6.
7.
8.
目的探讨应用护理方法对胃癌术后胃瘫的康复效果的影响。方法回顾性分析我院50例胃癌手术后胃瘫患者的临床资料及护理经验。结果本组涉及的50例患者均通过保守治疗手段治愈,其中30例在术后在3周内胃动力逐渐的得到了恢复,另外还有10例患者在术后4周内胃动力恢复,另外,10例42d内症状消失痊愈出院,大便正常,收到了良好的护理效果。结论在实际的护理过程中,不要急于求成,确诊后应采取严格保守疗法,治疗重点应在常规治疗基础上根据患者实际病情选用合适的治疗方案。 相似文献
9.
目的分析胃癌全胃切除结肠代胃术在临床上取得的治疗效果。方法回顾性分析我院收治的30例以全胃切除治疗胃癌的患者的临床资料。结果全部患者中间置结肠代胃13例(43.33%),幽门结肠代胃17例(56.67%)。同时治疗后对30例患者进行随访,1年死亡2例,生存率为93.33%;2年死亡4例,生存率86.67%;3年死亡8例生存率73.33%;5年死亡16例,生存率46.67%。术后半年患者恢复正常的一日三餐,日平均进食量控制在350g左右,进食后无饱胀感。术后体重恢复良好,血红蛋白、血清蛋白等生化值均维持在正常水平内。查肝肾功能、心电图正常。结论结肠代胃消化道重建术对于胃癌全胃切除患者术后早期营养状况的改善效果显著,值得临床广泛应用。 相似文献
10.
目的:探讨胃十二指肠溃疡术后并发症的诊断方法和处理措施。方法对10例胃十二指肠溃疡术后并发症的患者临床资料进行分析。结果所有发生术后并发症患者,保守治疗8例,2例二次手术治疗。所有患者经治疗症状渐趋缓解,最后治愈。结论胃十二指肠溃疡术后应密切观察,并发症应早发现、早治疗。 相似文献
11.
12.
目的:探讨内镜下大直径球囊扩张术治疗贲门失弛缓症的方法及疗效。方法内径下大直径球囊扩术治疗22例贲门失弛缓症患者,观察其临床症状,复查胃镜或X线,以了解其疗效。结果22例患者吞咽困难缓解率100%,其中一次操作成功率95.5%(21/22),两次扩张(1例先行沙氏条预扩)成功率4.5%(1/22)。术后出血行手术治疗1例,出现皮下气肿、纵膈气肿1例,经内科治疗后痊愈。复查胃镜或X线均较扩张前明显改善。随访3个月~2年,无一例复发。结论内镜下球囊扩张术是目前基层医院治疗贲门失弛缓症的较为理想的首选和主要治疗方法,其具有疗效确切、操作简单、费用低及痛苦小等优点。 相似文献
13.
14.
目的探讨腹主动脉球囊置入术与宫腔球囊填塞术治疗凶险性前置胎盘的效果。方法选取2019年1月~2020年1月105例凶险性前置胎盘患者为观察对象,按照随机数表法分为对照组52例和观察组53例。对照组采用宫腔球囊填塞术治疗,观察组采用腹主动脉球囊置入术+宫腔球囊填塞术治疗。比较两组出血量、输红细胞量、输血浆量、术后24 h出血量、术中胎盘植入、失血性休克、DIC率、子宫次全切除或全切除率、新生儿体重、Apgar 1 min评分、Apgar 5 min评分、新生儿窒息率。结果观察组出血量、输红细胞量、输血浆量、术后24 h出血量少于对照组(P<0.05);两组术中胎盘植入差异无统计学意义(P>0.05),观察组失血性休克、DIC率、子宫次全切除或全切除率低于对照组(P<0.05);两组新生儿体重、Apgar 1 min评分、Apgar 5 min评分、新生儿窒息率差异无统计学意义(P>0.05)。结论腹主动脉球囊置入术联合宫腔球囊填塞术治疗凶险性前置胎盘能够减少出血量、输血量、术后24 h出血量,降低失血性休克、DIC率、子宫次全切除或全切除率,改善孕产妇的预后。 相似文献
15.
目的探讨经支气管镜联合局部微波烧灼、球囊扩张和支架植入治疗结核性支气管狭窄的临床疗效。方法回顾性分析本院2006年1月-2010年12月经支气管镜检确诊并予以微波烧灼、球囊扩张和支架植入治疗的35例结核性支气管狭窄患者的临床资料,评价治疗前、后呼吸困难指数和1秒用力呼吸容积(FEVl)的改善情况。结果经支气管镜联合介入治疗结核性支气管狭窄的临床有效率为91.4%,其中25例经局部微波烧灼加球囊扩张治疗后好转,7例经支架植入治疗后好转。FEVl由治疗前的平均(1.54±0.21)L增加至术后的(2.48±0.32)L,差异有显著性(P〈0.05)。无严重并发症发生。结论支气管镜下联合介入治疗结核性支气管狭窄是一种安全有效的方法。 相似文献
16.
The prevalence of obesity has doubled in the last 10 years and is now reaching epidemic proportions. There is a significant comorbidity and financial cost associated with this disorder. Orlistat is an intestinal lipase inhibitor that is approved for the treatment of obesity.
Recent randomized, double-blind, placebo-controlled trials have demonstrated the benefit of orlistat used in conjunction with a hypocaloric (low-fat) diet in facilitating weight reduction and the long-term maintenance of this weight loss. Patients treated with orlistat lost a greater amount of initial body weight compared to those who received placebo. After 24 months of treatment, weight loss of more than 5% was maintained in a greater number of those treated with orlistat. This was associated with significant reductions in cardiovascular risk factors (cholesterol, LDL cholesterol, LDL:HDL cholesterol ratio). The main adverse events are related to fat malabsorption, with potential losses of fat-soluble vitamins and other compounds.
Orlistat as a treatment for obesity, when prescribed within present guidelines, can aid modest weight loss in about one-third of patients. More importantly, it can assist in the maintenance of weight loss with major medical benefits for these patients. 相似文献
Recent randomized, double-blind, placebo-controlled trials have demonstrated the benefit of orlistat used in conjunction with a hypocaloric (low-fat) diet in facilitating weight reduction and the long-term maintenance of this weight loss. Patients treated with orlistat lost a greater amount of initial body weight compared to those who received placebo. After 24 months of treatment, weight loss of more than 5% was maintained in a greater number of those treated with orlistat. This was associated with significant reductions in cardiovascular risk factors (cholesterol, LDL cholesterol, LDL:HDL cholesterol ratio). The main adverse events are related to fat malabsorption, with potential losses of fat-soluble vitamins and other compounds.
Orlistat as a treatment for obesity, when prescribed within present guidelines, can aid modest weight loss in about one-third of patients. More importantly, it can assist in the maintenance of weight loss with major medical benefits for these patients. 相似文献
17.
目的:探讨无痛胃镜检查的人群分布,镜下疾病谱和安全性.方法:回顾性分析1 580例无痛胃镜检查.按年龄、镜下疾病及检查过程中出现低氧血症、低血压、球囊面罩使用、终止检查等进行统计分析.结果:镜下疾病以胃十二指肠疾病为主,约33.2%病人缓慢静脉注射丙泊酚后出现低氧血症.11.5%病人缓慢静脉注射丙泊酚后出现低血压,使用球囊面罩人工呼吸8例,2例未完成检查.结论:无痛胃镜检查病人满意度高,较安全可靠,利于治检.检查以中老年病人较多,镜下疾病以慢性胃炎为主,但注意检查前知情告知,防治呼吸循环抑制仍很重要. 相似文献
18.
目的比较无痛胃镜及普通胃镜的诊疗效果,总结无痛胃镜护理中的注意事项。方法对我院消化内科自2010年1月至2012年12月间收治并行无痛胃镜检查的86例患者采取随机分组的方式分为治疗组和对照组,治疗组采取无痛胃镜检查,对照组采取常规胃镜检查,两组均进行术前、术中、术后的全程配合护理,记录护理步骤及患者生命体征、治疗效果及并发症发生情况。结果 观察组不良反应、操作过程中生命体征波动低于对照组,观察组操作成功率及满意度高于对照组。结论无痛胃镜比常规胃镜具有术中刺激小,操作成功率高,患者满意度高的优势,但也额外增加了麻醉因素导致的风险,需要医护人员更好的配合治疗。 相似文献
19.
《Expert opinion on pharmacotherapy》2013,14(12):2141-2144
Orlistat and sibutramine are the most commonly used drugs in the reduction of body weight, but both of these result in only modest weight reduction. In diet-induced obesity of the mouse, the cannabinoid CB1 receptor antagonist rimonabant induced a marked, sustained reduction of body weight and obesity. In the first major clinical trial (Rimonabant in Obesity), patients were put on a hypocaloric diet, which lead to weight loss of 3.6 kg after 1 year. This weight loss was increased to 8.6 kg by treatment with rimonabant 20 mg/day for the year. Discontinuations due to nausea, vomiting, diarrhoea and headache were more common in the rimonabant 20 mg/day group than the placebo group, but occurred in very few patients. Rimonabant is an addition to the available drugs for the treatment of obesity. 相似文献
20.
Mauri M Castrogiovanni S Simoncini M Iovieno N Miniati M Rossi A Dell'Agnello G Fagiolini A Donda P Cassano GB 《Journal of clinical psychopharmacology》2006,26(5):462-466
BACKGROUND: Increasing numbers of reports have raised concerns about significant increases in weight and adiposity over both short- and long-term treatment in patients treated with antipsychotics (APs). The management of overweight and obesity in patients treated with APs has included pharmacological interventions, dietary suggestions, and behavioral strategies. Nevertheless, current evidence does not support the use of pharmacological management of this specific type of obesity, and only a limited number of studies have been published regarding prevention and treatment of weight gain with other strategies. OBJECTIVE: The aim of this study was to evaluate the effectiveness of an educational intervention (EI) that combines low-calorie diet with increased physical activity to prevent and treat weight gain in patients treated with APs. METHOD: Data were from 53 subjects whose body mass index (BMI) had increased by more than 7% after starting an AP therapy and who consented to participate in a 12-week educational intervention study aimed at preventing further weight gain and, when possible, at inducing a weight loss. Weight and BMI were measured at baseline (at each of the monthly follow-up visits) and at study completion 12 weeks from entry in the study. RESULTS: Twenty-six patients completed the 12-week program. Completers showed a significant mean body weight decrease of 3.15 kg, with a mean BMI reduction of 1.2 (kg/m) at the end of the 3-month period. CONCLUSIONS: Educational intervention can be an important tool for the management of weight increase in patients treated with APs. A larger prospective and controlled study is now needed to confirm our findings. 相似文献